CA2002182A1 - Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi - Google Patents
Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploiInfo
- Publication number
- CA2002182A1 CA2002182A1 CA 2002182 CA2002182A CA2002182A1 CA 2002182 A1 CA2002182 A1 CA 2002182A1 CA 2002182 CA2002182 CA 2002182 CA 2002182 A CA2002182 A CA 2002182A CA 2002182 A1 CA2002182 A1 CA 2002182A1
- Authority
- CA
- Canada
- Prior art keywords
- methods
- compositions
- premenstrual
- treating
- luteal phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000029849 luteinization Effects 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 abstract 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 229960004597 dexfenfluramine Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960002464 fluoxetine Drugs 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 230000002295 serotoninergic effect Effects 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2002182 CA2002182C (fr) | 1989-11-03 | 1989-11-03 | Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2002182 CA2002182C (fr) | 1989-11-03 | 1989-11-03 | Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2002182A1 true CA2002182A1 (fr) | 1991-05-03 |
| CA2002182C CA2002182C (fr) | 2000-06-13 |
Family
ID=4143458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2002182 Expired - Fee Related CA2002182C (fr) | 1989-11-03 | 1989-11-03 | Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2002182C (fr) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006108591A1 (fr) | 2005-04-11 | 2006-10-19 | Novartis Ag | 1h-quinaz0line-2,4-diones et leur utilisation en tant que ligands du recepteur ampa |
| EP2336129A1 (fr) | 2004-06-18 | 2011-06-22 | Novartis AG | 1-aza-bicyclo[3.3.1]nonanes |
| EP2354141A1 (fr) | 2005-12-16 | 2011-08-10 | Novartis AG | (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines en tant que ligands cholinergiques du n-achr pour le traitement de troubles psychotiques et neurodegeneatifs |
| EP2361914A1 (fr) | 2005-12-16 | 2011-08-31 | Novartis AG | [(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes comme ligands cholinergiques de n-achr pour le traitement des troubles psychotiques et neurodegeneratifs. |
| EP2457911A1 (fr) | 2004-07-14 | 2012-05-30 | Novartis AG | Dérivés de 3-(hétéroaryl-oxy)-2-alkyl-1-aza-bicycloalkyle en tant que ligands nAChR alpha7 pour le traitement des maladies du SNC |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| WO2020237325A1 (fr) * | 2019-05-31 | 2020-12-03 | Alyra Biotech Pty Ltd | Procédés, compositions et dispositifs pour traiter des états neuroinflammatoires |
-
1989
- 1989-11-03 CA CA 2002182 patent/CA2002182C/fr not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2336129A1 (fr) | 2004-06-18 | 2011-06-22 | Novartis AG | 1-aza-bicyclo[3.3.1]nonanes |
| EP2457911A1 (fr) | 2004-07-14 | 2012-05-30 | Novartis AG | Dérivés de 3-(hétéroaryl-oxy)-2-alkyl-1-aza-bicycloalkyle en tant que ligands nAChR alpha7 pour le traitement des maladies du SNC |
| WO2006108591A1 (fr) | 2005-04-11 | 2006-10-19 | Novartis Ag | 1h-quinaz0line-2,4-diones et leur utilisation en tant que ligands du recepteur ampa |
| EP2463278A1 (fr) | 2005-04-11 | 2012-06-13 | Novartis AG | 1h-quinaz0line-2,4-diones et leur utilisation en tant que ligands du recepteur ampa |
| EP2468732A1 (fr) | 2005-04-11 | 2012-06-27 | Novartis AG | 1H-quinazoline-2,4-diones |
| EP2476671A1 (fr) | 2005-04-11 | 2012-07-18 | Novartis AG | 1H-quinazoline-2,4-diones |
| EP2354141A1 (fr) | 2005-12-16 | 2011-08-10 | Novartis AG | (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines en tant que ligands cholinergiques du n-achr pour le traitement de troubles psychotiques et neurodegeneatifs |
| EP2361914A1 (fr) | 2005-12-16 | 2011-08-31 | Novartis AG | [(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes comme ligands cholinergiques de n-achr pour le traitement des troubles psychotiques et neurodegeneratifs. |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2002182C (fr) | 2000-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2001572A1 (fr) | Composes pour le traitement des symptomes de sevrage du tabac | |
| EP0419653A4 (en) | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof | |
| DE69202207D1 (de) | Verfahren zur Herstellung von 1-Chlor-1,1,3,3,3-Pentafluorpropan und von 1,1,1,3,3,3-Hexafluorpropan. | |
| HU901325D0 (en) | Process for preparation of 4-phenyl-1,2,3,4-tetrahydro-1-naphthaleneamine derivatives | |
| IL96458A0 (en) | Isoxazolines,their preparation,and their use as plantprotecting agents | |
| AU5642294A (en) | Bacteriocidal gas composition and process for preparing the same | |
| AU2566892A (en) | Composition suitable for forming into shaped articles, process for preparing the composition, process for preparing shaped articles using the composition, and shaped articles so-formed | |
| EP0391774B1 (fr) | Procédé de synthèse de précurseurs de tamis moléculaires du type silicoaluminophosphate, précurseurs obtenus et leur application à l'obtention desdits tamis moléculaires. | |
| DE3856295D1 (de) | Behandlung des prämenstruellen oder späten lutealsphase-syndroms | |
| HUT47103A (en) | Process for producing 1,4-benzoxazine derivatives and pharmaceutical compositions comprising the same | |
| AU7239794A (en) | Process for preparing 5,8-dihydronaphthoquinone derivatives, novel 5,8-dihydronaphthoquinone derivatives and their use as anticancer agent | |
| CA2002182A1 (fr) | Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi | |
| PT66089A (en) | Process for preparing 1,2-benzisothiazolin-3-ona with anti-thrombotic effect,application of same for the preparation of pharmaceutical compositions with anti-thrombic effect and application of these pharmaceutical compositions for the treatment of thrombosis | |
| EP0264744A3 (en) | Process for the preparation of 4,4'-diaminodiphenylmethane and its derivatives. | |
| ZA925892B (en) | Organic nitrates, processes for their preparation and their use in the treatment of cardiovascular diseases. | |
| EP0318233A3 (fr) | Inhibiteurs d'assimilation de sérotonine et de norépinéphrine | |
| IL93339A0 (en) | 2,3,23-trihydroxy-urs-12-ene and its derivatives,processes for their preparation and their use | |
| LTIP911A (en) | Indenoindole compounds i,process for preparing thereof,pharmaceutical compositions containing this compounds,and their use | |
| ZA898775B (en) | Cyclopropyl-substituted azolylmethylcarbinols,processes for their preparation and their use as medicaments | |
| ZA906744B (en) | Novel aminopropanol derivatives,process for their preparation and pharmaceutical compositions comprising the same | |
| IL95210A0 (en) | 14,17alpha-etheno-and-ethanoestratrienes,process for the preparation thereof and pharmaceutical compositions containing the same | |
| CA2019745A1 (fr) | Preparation pour le traitement et la prevention des thromboses et des complications thromboemboliques, utilisation d'une telle preparation et methode de production | |
| EP0386920A3 (fr) | Dérivés d'hydroxy-2-thiénylox-3-propylamine | |
| ZA893310B (en) | Novel strobilurine derivatives,their preparation and their use | |
| IL95088A0 (en) | Pyrroloquinoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |